Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NTAP News 24 December 2025 - 6 February 2026

Seagate stock price jumps 5% as Citi lifts target; STX steadies after a choppy week

Seagate stock price jumps 5% as Citi lifts target; STX steadies after a choppy week

Seagate shares jumped nearly 5% to $425.61 midday Friday after Citigroup raised its price target to $480, maintaining a buy rating. The stock swung between $400.52 and $428.90 during the session, rebounding from a 3% drop Thursday. Other storage stocks, including Western Digital and Pure Storage, also rose. Trading volume in Seagate exceeded its 50-day average.
6 February 2026
·····
Western Digital stock steadies after Cantor target hike as traders eye earnings and a new leveraged ETF

Western Digital stock steadies after Cantor target hike as traders eye earnings and a new leveraged ETF

Western Digital shares rose 1.9% to $240.85 in after-hours trading Monday after Cantor Fitzgerald raised its price target to $300. The stock swung between $233.53 and $250.31 during the session. Seagate reports earnings Tuesday, with Western Digital’s results due Thursday after the bell. A 2x leveraged Western Digital ETF launches Tuesday on Cboe.
27 January 2026
·····
Trump’s Greenland tariff threat jolts Wall Street again as S&P 500’s biggest losers pile up

Trump’s Greenland tariff threat jolts Wall Street again as S&P 500’s biggest losers pile up

U.S. stocks rebounded Wednesday after Tuesday’s sharp sell-off triggered by Trump’s tariff threats over Greenland. By 9:38 a.m. ET, the Dow rose 0.42%, the S&P 500 gained 0.40%, and the Nasdaq edged up 0.20%. Netflix dropped 4.2% after suspending buybacks to fund its Warner Bros Discovery deal. NetApp, Dell, and Norwegian Cruise Line led losses in the previous session.
21 January 2026
·····
Seagate Technology (STX) Stock After Hours Today, Dec. 24, 2025: What Happened After the Bell and What to Watch Before Markets Reopen

Seagate Technology (STX) Stock After Hours Today, Dec. 24, 2025: What Happened After the Bell and What to Watch Before Markets Reopen

Seagate Technology Holdings plc (NASDAQ: STX) ended Christmas Eve’s holiday-shortened session in positive territory, then eased modestly in after-hours trading—a familiar pattern on a low-liquidity day when most institutional desks are lightly staffed and spreads can widen. Here’s what investors should know after the bell on Wednesday, Dec. 24, 2025, and what to keep on the radar before U.S. markets reopen. STX after the bell: Seagate finishes higher, then dips slightly after hours Seagate shares closed up 1.14% at $285.27 in the shortened regular session. MarketWatch+1 In after-hours trading, STX was $284.56, down $0.71 (-0.25%) as of 4:47:48 p.m. ET.
24 December 2025
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop